Registered entities
Outlook Therapeutics, Inc.
Reg. No. 214304099United States
Oncobiologics Inc
Reg. No. 383982704United States
ONCOBIOLOGICS, INC.
Reg. No. 1649989United States
Innovation
9 patent families (5 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace slowing. Cited 901 times.
| Year | Filings |
|---|---|
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
Social engagement
Social engagement: 13.4K social following, 10 posts in the last 12 months — around the industry typical range.
Investor mix
14 investors on record; lead investors include Perceptive Advisors; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 36% |
| Private equity | 4 | 29% |
| Angel & family office | 1 | 7% |
| Other / undisclosed | 4 | 29% |
Recent activity
16 Jun 2026
Product launch
ONS-5010/LYTENAVATM (bevacizumab-vikg)
28 May 2026
Milestone
revenue